In the anti-tumor M2 module, cDC2 was positioned at the most upstream level, capable of activating Macro_INHBA, Mono_FCN1, and various T cells, while CD8_Teff and Trm were downstream recipients of regulatory signals (Figure 3B). The gene discussed is CD8A; the disease is neoplasm.